TCDB is operated by the Saier Lab Bioinformatics Group
TCIDNameDomainKingdom/PhylumProtein(s)
9.B.364.1.1









Putative arabinosyltransferase B of 1083 aas and 13 putative TM

Bacteria
Actinobacteria
AraTB of Hoyosella subflava (Amycolicicoccus subflavus)
9.B.364.1.2









Uncharacterized protein of 1050 aas and 13 TMSs in a 1 (N-terminal) + 2 + 2 + 2 + 6 TMS arrangement.

Bacteria
Actinobacteria
UP of Pseudonocardia autotrophica
9.B.364.1.3









Uncharacterized protein of 1209 aas and 13 TMSs in a 1 + 6 + 6 TMS arrangement.

Bacteria
Actinobacteria
UP of Quadrisphaera sp. DD2A
9.B.364.1.4









Uncharacterized protein of 995 aas and 15 TMSs in a 1 + 2 + 6 + 6 TMS arrangement.

Bacteria
Actinobacteria
UP of Saccharomonospora saliphila
9.B.364.1.5









Aarabinosyltransferases, EmbAB and dimeric EmbC, with subunits of 1094, 1098 and 1094 aas, respectively, and all with about 14 TMSs.  The structure of the cell wall arabinosyltransferase complex with the anit-tuberculosis drug, ethambutol, bound has been solved (Zhang et al. 2020). The arabinosyltransferases EmbA, EmbB, and EmbC are involved in Mycobacterium tuberculosis cell wall synthesis and are targets for the anti-tuberculosis drug ethambutol. Zhang et al. 2020 determined cryo-electron microscopy and x-ray crystal structures of the mycobacterial EmbA-EmbB and EmbC-EmbC complexes in the presence of their glycosyl donor and acceptor substrates and with ethambutol. These structures show how the donor and acceptor substrates bind in the active site and how ethambutol inhibits arabinosyltransferases by binding to the same site as both substrates in EmbB and EmbC. Most drug-resistant mutations are located near the ethambutol binding site.

Bacteria
Actinobacteria
EmbAB and EmbC2 of Mycobacterium tuberculosis